Published • loading... • Updated
Italy's Angelini to Buy Catalyst Pharma for $4.1 Billion in US Market ...
The deal gives Angelini Pharma a rare-disease portfolio and U.S. commercial platform as it targets growth in North America, the companies said.
- On Thursday, May 7, 2026, Italian pharmaceutical company Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals for $4.1 billion in cash, marking the drugmaker's entry into the U.S. pharmaceutical market.
- This acquisition reinforces Angelini Pharma's long-term commitment to Brain Health and Rare Diseases, establishing the company as a global player with the scale and capabilities needed to expand into the United States.
- Angelini will pay $31.50 per share, a 28% premium, for Catalyst's portfolio including FDA-approved treatments FIRDAPSE, AGAMREE, and FYCOMPA, which Catalyst acquired from Eisai in 2023.
- Catalyst CEO Rich Daly called the acquisition a "pivotal and transformative moment," saying the combined platform will enhance patient support and accelerate innovation for stakeholders worldwide.
- Separately, Catalyst resolved patent litigation regarding a generic version of FIRDAPSE filed by Hetero USA, while the transaction remains subject to regulatory approval with closing expected in the third quarter of 2026.
Insights by Ground AI
17 Articles
17 Articles
The transaction marks the entry of Italian society into the US market and its strengthening in the area of the nervous system and rare diseases
·Milan, Italy
Read Full Article
Coverage Details
Total News Sources17
Leaning Left2Leaning Right1Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 20%
C 70%
Factuality
To view factuality data please Upgrade to Premium
